CE
Therapeutic Areas
BigHat Biosciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Proprietary Pipeline | Undisclosed intractable diseases (e.g., cancers, immune disorders) | Discovery/Preclinical |
| Lilly Collaboration Program(s) | Undisclosed | Discovery |
| Synaffix (Lonza) ADC Collaboration | Undisclosed (Oncology-focused ADC) | Discovery |